Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines

被引:0
作者
Temchura, Vladimir [1 ]
Ueberla, Klaus [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany
关键词
HIV-1 envelope antibody; intrastructural help; T-helper cell; vaccine; T-CELLS; NEUTRALIZING ANTIBODIES; INTERNAL COMPONENTS; DOUBLE-BLIND; EFFICACY; IMMUNIZATION; INFECTION; RISK; ENV; SPECIFICITY;
D O I
10.1097/COH.0000000000000358
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review The importance of IgG Fc-effector functions for the efficacy of HIV vaccines is increasingly recognized. Although different types of vaccines were shown to induce antibodies with different Fc-activities, there is no clear strategy how to raise antibody responses with a desired pattern of Fc-effector functions. Given the central role of T-helper cells in regulating the germinal center reaction and the differentiation of B cells in an antigen-specific manner, the review will discuss whether T-helper cells directed against non-HIV envelope (Env) antigens could be harnessed to improve the HIV-Env antibody response. Recent findings Comparing CD4(+) T-cell responses in HIV-infected individuals with and without neutralizing antibody breadth suggests that robust Gag-specific CD4(+) T cells may provide important T-cell help to Env-specific B cells. In a murine model, GagPol-specific T-helper cells were shown to provide intrastructural help for HIVEnv- specific antibody responses after immunization with a virus-like particle vaccine. GagPol-specific Thelper cells imprinted the IgG subtype ratio observed for Gag onto the HIV-Env antibody response and modulated the glycosylation pattern of the HIV Env-specific antibodies. Summary Intrastructural help is a promising strategy to improve overall levels and Fc-effector functions of the HIV-Env antibody response.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 46 条
[11]   Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines [J].
Chung, Amy W. ;
Ghebremichael, Musie ;
Robinson, Hannah ;
Brown, Eric ;
Choi, Ickwon ;
Lane, Sophie ;
Dugast, Anne-Sophie ;
Schoen, Matthew K. ;
Rolland, Morgane ;
Suscovich, Todd J. ;
Mahan, Alison E. ;
Liao, Larry ;
Streeck, Hendrik ;
Andrews, Charla ;
Rerks-Ngarm, Supachai ;
Nitayaphan, Sorachai ;
de Souza, Mark S. ;
Kaewkungwal, Jaranit ;
Pitisuttithum, Punnee ;
Francis, Donald ;
Michael, Nelson L. ;
Kim, Jerome H. ;
Bailey-Kellogg, Chris ;
Ackerman, Margaret E. ;
Alter, Galit .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (228)
[12]   Vaccine Adjuvants: Putting Innate Immunity to Work [J].
Coffman, Robert L. ;
Sher, Alan ;
Seder, Robert A. .
IMMUNITY, 2010, 33 (04) :492-503
[13]   A novel assay for detecting virus-specific antibodies triggering activation of Feγ receptors [J].
Corrales-Aguilar, Eugenia ;
Trilling, Mirko ;
Reinhard, Henrike ;
Merce-Maldonado, Eva ;
Widera, Marek ;
Schaal, Heiner ;
Zimmermann, Albert ;
Mandelboim, Ofer ;
Hengel, Hartmut .
JOURNAL OF IMMUNOLOGICAL METHODS, 2013, 387 (1-2) :21-35
[14]   Virus-like Particle (VLP) Lymphatic Trafficking and Immune Response Generation After Immunization by Different Routes [J].
Cubas, Rafael ;
Zhang, Sheng ;
Kwon, Sunkuk ;
Sevick-Muraca, Eva M. ;
Li, Min ;
Chen, Changyi ;
Yao, Qizhi .
JOURNAL OF IMMUNOTHERAPY, 2009, 32 (02) :118-128
[15]   Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120 [J].
Daly, LM ;
Johnson, PA ;
Donnelly, G ;
Nicolson, C ;
Robertson, J ;
Mills, KHG .
VACCINE, 2005, 23 (07) :963-974
[16]   Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study) [J].
Duerr, Ann ;
Huang, Yunda ;
Buchbinder, Susan ;
Coombs, Robert W. ;
Sanchez, Jorge ;
del Rio, Carlos ;
Casapia, Martin ;
Santiago, Steven ;
Gilbert, Peter ;
Corey, Lawrence ;
Robertson, Michael N. .
JOURNAL OF INFECTIOUS DISEASES, 2012, 206 (02) :258-266
[17]   A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells [J].
Eller, Michael A. ;
Slike, Bonnie M. ;
Cox, Josephine H. ;
Lesho, Emil ;
Wang, Zhining ;
Currier, Jeffrey R. ;
Darden, Janice M. ;
Polonis, Victoria R. ;
Vahey, Maryanne T. ;
Peel, Sheila ;
Robb, Merlin L. ;
Michael, Nelson L. ;
Marovich, Mary A. .
PLOS ONE, 2011, 6 (09)
[18]   A brief history of the global effort to develop a preventive HIV vaccine [J].
Esparza, Jose .
VACCINE, 2013, 31 (35) :3502-3518
[19]   Nonneutralizing Functional Antibodies: a New "Old" Paradigm for HIV Vaccines [J].
Excler, Jean-Louis ;
Ake, Julie ;
Robb, Merlin L. ;
Kim, Jerome H. ;
Plotkin, Stanley A. .
CLINICAL AND VACCINE IMMUNOLOGY, 2014, 21 (08) :1023-1036
[20]   Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection [J].
Fouts, Timothy R. ;
Bagley, Kenneth ;
Prado, Ilia J. ;
Bobb, Kathryn L. ;
Schwartz, Jennifer A. ;
Xu, Rong ;
Zagursky, Robert J. ;
Egan, Michael A. ;
Eldridge, John H. ;
LaBranche, Celia C. ;
Montefiori, David C. ;
Le Buanec, Helene ;
Zagury, Daniel ;
Pal, Ranajit ;
Pavlakis, George N. ;
Felber, Barbara K. ;
Franchini, Genoveffa ;
Gordon, Shari ;
Vaccari, Monica ;
Lewis, George K. ;
DeVico, Anthony L. ;
Gallo, Robert C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (09) :E992-E999